Shots:
- FDA approved Sotyktu(6mg, PO, QD) for adults with active PsA based on 2 P-III trials against PBO, with POETYK PsA-1 involving 670 bDMARD-naïve pts while POETYK PsA-2 involved 624 pts who were bDMARD-naïve & treated with prior TNFα inhibitor
- POETYK PsA-1 showed that 54% pts achieved ACR20 compared to 34%, while 24% vs 14% reached ACR50, & 12% vs 5% reached ACR70, with 19% vs 10% attaining minimal disease activity (MDA) response at Wk. 16
- In POETYK PsA-2, 54% pts achieved ACR20 vs 39%, while 29% vs 16% reached ACR50, & 10% vs 5% reached ACR70, with 26% vs 15% attaining MDA response at Wk. 16; Both trials showed improved QoL with higher SF-36 PCS scores at Wk. 16
Ref: Businesswire | Image: BMS | Press Release
Related News: BMS Reports the US FDA’s NDA Acceptance for Iberdomide Combination in R/R Multiple Myeloma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
